According to CASI Pharmaceuticals's latest financial reports the company's current revenue (TTM ) is HK$0.17 Billion. In 2023 the company made a revenue of HK$0.26 Billion a decrease over the revenue in the year 2022 that were of HK$0.33 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2024 (TTM) | HK$0.17 B | -34.99% |
2023 | HK$0.26 B | -21.44% |
2022 | HK$0.33 B | 43.18% |
2021 | HK$0.23 B | 100.41% |
2020 | HK$0.11 B | 264.83% |
2019 | HK$32.17 M | |
2018 | N/A | |
2017 | N/A | |
2016 | N/A | -100% |
2015 | HK$0.36 M | 100.94% |
2014 | HK$0.18 M | |
2013 | N/A | -100% |
2012 | HK$5.18 M | -65.58% |
2011 | HK$15.07 M | -47.55% |
2010 | HK$28.74 M | -29.85% |
2009 | HK$40.97 M | |
2005 | HK$45.88 M | 1048.73% |
2004 | HK$3.99 M | -67.29% |
2003 | HK$12.21 M | 33.11% |
2002 | HK$9.17 M | -36.81% |
2001 | HK$14.51 M | -49.3% |
2000 | HK$28.63 M | -25.88% |
1999 | HK$38.63 M | -4.1% |
1998 | HK$40.28 M | 8.31% |
1997 | HK$37.19 M | 9.3% |
1996 | HK$34.03 M |